Key Highlights

  • Shares trading up 5.48% pre-market, adding $0.30 to reach $5.77
  • Move extends Tuesday's 12.32% regular-session rebound, following Monday's sharp selloff on Phase 3 trial data
  • The Phase 3 LUGANO trial did not meet its primary efficacy endpoint against on-label aflibercept in the full study population
  • A post-hoc analysis excluding a small subset of patients showed non-inferiority to the control, though this was not the trial's pre-specified primary analysis
  • Secondary endpoints showed a 42% reduction in treatment burden compared to on-label aflibercept
  • A second pivotal Phase 3 trial, LUCIA, is expected to read out in the fourth quarter of 2026

Shares Extend Rebound From Monday's Selloff

EyePoint Pharmaceuticals (NASDAQ:EYPT) shares are trading up 5.48% in pre-market action Wednesday to $5.77, extending Tuesday's 12.32% regular-session rebound. The stock had collapsed Monday after the company reported that its pivotal Phase 3 LUGANO trial evaluating DURAVYU 2.7mg in wet age-related macular degeneration did not meet its primary efficacy endpoint against on-label aflibercept in the full study population.

EyePoint Pharmaceuticals is a Watertown, Massachusetts-based biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal and ocular diseases. Its proprietary Durasert E bioerodible sustained-release technology underlies its lead pipeline candidate, DURAVYU, formerly EYP-1901, a selective tyrosine kinase inhibitor currently in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema.

Trial Result Was Mixed, Not a Clean Win

In an ad hoc analysis that excluded a small subset of patients, roughly 4% of the study population who experienced vision loss unrelated to wet AMD, DURAVYU showed non-inferiority to the aflibercept control. However, this was not the trial's pre-specified primary analysis, and the primary endpoint was not achieved when the full dataset was included. The company characterized several secondary endpoints as clinically meaningful, including a 42% reduction in treatment burden that achieved statistical superiority over on-label aflibercept, along with favorable rates of patients remaining supplement-free, a favorable safety profile with redosing, and strong anatomic control through week 56.

Following Monday's selloff, several analysts downgraded the stock and cut price targets, even as some firms flagged potential upside if the second pivotal trial, LUCIA, reads out positively when data is expected in the fourth quarter of 2026. The stock's rebound over the past two sessions suggests some investors are viewing the current valuation as reflecting a comparatively de-risked, potential buyout candidate following the selloff, even as the company continues to hold that LUGANO's secondary results reinforce DURAVYU's potential in wet AMD.

Conclusion

EyePoint Pharmaceuticals' continued pre-market gain reflects an ongoing rebound from Monday's sharp selloff rather than a fresh positive catalyst, following a Phase 3 trial that missed its primary endpoint in the full study population even as secondary measures showed meaningful benefits. With a second pivotal trial due to read out in the fourth quarter, the stock's next moves will likely hinge on whether LUCIA can deliver a cleaner result on the primary endpoint that LUGANO was unable to achieve.